Abstract: The present invention provides a hybrid biocompatible carrier (hybridosome) which comprises structural and bioactive elements originating from at least one biocompatible delivery module (BDM) and at least one engineered drug encapsulation module (EDEM) comprising at least one tunable fusogenic moiety. The invention further provides pharmaceutical compositions comprising said hybridosomes, processes for their manufacture, as well as pharmaceutical uses and pharmaceutical methods based thereon.

Abstract: Disinfecting compositions containing hypochlorous acid and acetic acid are useful for treating biofilms in or on tissue, including biofilms related to wounds or other skin trauma. The compositions are useful for treating a variety of types of tissue, both on the surface on beneath the surface of tissue. Compositions are provided for treating biofilms without inducing antimicrobial resistance.

Abstract: A method of preparing a radioactive yttrium phosphate particle suspension.

Abstract: The present invention relates to the medical field, in particular to the enhancement of brain performances and for the treatment of pathological stress. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use in enhancing brain performances or in prevention or treatment of pathological stress in a subject without exposure of the nanoparticle or nanoparticles' aggregate to an electric field, and preferably without exposure thereof to any other external activation source, wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant ?ijk equal to or above (200), and an insulator material with a dielectric constant ?ijk equal to or below (100).

Abstract: The present invention relates to stable pharmaceutical compositions of sulfur colloid, which advantageously provide a high radiochemical purity to 99mTc-pertechnetate without causing the gel formation. The compositions include pre-lyophilized and lyophilized compositions of sulfur colloid. It also relates to a non-radioactive kit which upon reconstitution with 99mTc-pertechnetate solution gives stabilized 99mmTc-Sulfur colloid radiopharmaceutical composition. Further, the process for preparation of said compositions and their use for diagnostic purposes are also disclosed.

Abstract: Provided is use of miR-21 in preparation of a therapeutic drug or diagnostic reagent for intrauterine adhesion and/or thin endometrium.

Abstract: The present invention provides an improved process for preparing microparticles containing glatiramer acetate having low levels of residual organic solvent(s), in particular dichloromethane. The microparticles are incorporated into long acting parenteral pharmaceutical compositions in depot form that are suitable for subcutaneous or intramuscular implantation or injection, and that may be used to treat multiple sclerosis.

Abstract: The present invention is inserted in the fields of nanotechnology, pharmacy and genetics and refers to specific sequences of interference RNA (siRNA), capable of silencing the gene responsible for the expression of an adhesion protein, which produces overexpressed extracellular adenosine in tumors, the enzyme ecto-5?-nucleotidase/CD73 (CD73). The specific siRNA sequences for CD73 are proposed in a nanometer scale composition in the form of liposomes or nanoemulsions in order to promote a site-directed release complex capable of being incorporated into several types of formulation, such as intratumor, intravenous injection or administration nasal. The siRNA sequences to silence CD73 can also be applied in the manufacture of kits and/or in silencing tests of CD73 for scientific research using liposomes, nanoemulsions or other transfection reagents.

Abstract: The present invention discloses a method for synthesizing a new ferrihydrite nano-photosensitizer, comprising steps of: weighing 303 mg of Fe(NO3)3?9H2O solid dissolved fully in 30 ml of distilled water to prepare a 0.75 mM of Fe(NO3)3 solution in water; adding PEG solid to the solution in water by stirring to fully dissolve at a molar ratio of PEG to Fe3+ of 1:1-1:50; stirring the obtained solution under heating at 75° C. in a water bath for 10-50 minutes, and then immediately cooling in an ice bath after removing; centrifuging and washing the cooled mixed solution at high speed under low temperature with the supernatant discarded, to obtain pellets as PEG-modified ferrihydrite nanoparticles (PEG-Fns). The PEG-Fns synthesized in the present invention can be controllably induced and reduced by blue light to release Fe2+, and then produce ?OH through Fenton reaction of Fe2+ and H2O2 in the cell, which induces cell oxidative damage, thereby achieving controllable anticancer and antibacterial purposes.

Abstract: Compositions comprising a fluorescein component and benoxinate component and the corresponding uses of these compositions are described herein. These compositions have improved storage life and the fluorescein component and/or benoxinate component minimally degrade after 12 to 18 months of storage.

Abstract: Disinfecting compositions containing hypochlorous acid and acetic acid are useful for treating transient biofilms in or on tissue without harming the natural flora of the tissue. The compositions are useful for treating a variety of types of tissue. Compositions are useful for treating and preventing orally-associated biofilm. Compositions may be provided in mouthwash form, spray form, gel form, cream form, dentifrice form, and may include nanoparticle encapsulated molecules for controlled release.

Abstract: Non-viral nucleic acid delivery agents and methods for the delivery or transfer of nucleic acid molecules to target cells are disclosed. The agents comprise a complex of a nucleic acid cargo for delivery, one or more lipopeptide compound, and one or more polymeric charge-neutralising agent, and the complex is in the form of a particle with substantially neutral or negative surface charge. The agents and methods may be useful in a variety of applications such as therapies (including gene therapies and nucleic acid vaccinations) for diseases and medical disorders.

Abstract: The present disclosure discloses an application method of silicon quantum dots (Si QDs) for controlling corn armyworm, belonging to the technical field of nano-agricultural technology for crop pest control. The method for controlling corn armyworm by using Si QDs of the present disclosure includes the following steps of: preparing the Si QDs into an aqueous solution of the Si QDs, and then applying the aqueous solution on the roots or leaves of plants as plant fertilizer; where the concentration of the aqueous solution of the Si QDs is 10-150 mg/L; the size of the Si QDs is 3-8 nm. The method of the present disclosure not only improves the effect of the conventional silicon fertilizer on the stress resistance of plants, but also directly improves the direct insecticidal effect of the nano-silicon and improves the chemical defense capability of plants; the optimal spraying amount of Si QDs is determined by spraying different concentrations of Si QDs in the growth and development experiment of armyworm.

Abstract: The present invention relates to a method for the preparation of a colloidal aqueous suspension of stable zeolite nanocrystals having framework structures comprising at least one cation selected from Gd, Fe, Cu and Ce, said structures being loaded with a gas selected from O2, CO2 and mixtures thereof, to the colloidal aqueous suspension of zeolite nanocrystals obtained by such a process, and to the use of said suspension in therapy, more particularly in cancer therapy and hypoxia-related diseases and/or in diagnosis.

Abstract: The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo.

Abstract: The invention provides a droplet encapsulate comprising: a drop of a hydrophobic medium; a peripheral layer of non-polymeric amphipathic molecules around the surface of the drop; and an aqueous droplet within the peripheral layer, the aqueous droplet comprising: (a) an aqueous medium and (b) an outer layer of non-polymeric amphipathic molecules around the surface of the aqueous medium. The invention also provides processes for preparing the droplet encapsulates. Various uses of the droplet encapsulates are also described, including their use as drug delivery vehicles, in synthetic biology, and in the study of membrane proteins.

Abstract: The present invention concerns a luminescent particle comprising a nanoparticle of formula A1-xLnxVO4(1-y)(PO4)y??(I) in which A is selected from yttrium (Y), gadolinium (Gd), lanthanum (La), and mixtures thereof; Ln is selected from europium (Eu), dysprosium (Dy), samarium (Sm), neodymium (Nd), erbium (Er), ytterbium (Yb), and mixtures thereof; 0<x<1; and 0?y<1; characterized in that the nanoparticle on its surface has tetraalkylammonium cations in an amount such that said nanoparticle has a zeta potential, ?, of less than or equal to ?28 mV in an aqueous medium with a pH?5, more particularly with a pH?5.5, and with an ionic conductivity >100 ?S·cm?1. It also concerns a method for preparing such luminescent particles, a colloidal suspension of these particles, and the use thereof as a diagnostic agent, and also a diagnostic kit comprising such luminescent particles.

Abstract: Methods are taught for treating chronic wounds and skin and soft tissue infections with antibiotic tumescent injection. In such methods, the region of tumescent drug delivery is monitored and expanded by the infusate in order to be 2×-5× larger in area and volume in the region of the wound or infection, the drug in the infusate creates a tissue concentration greater than the MIC in the tumescent volume for selected period of time, and the high concentration has a residence lifetime in the tissue long enough to kill the bacteria. Typically, the methods are performed without the use of vasoconstrictors such as epinephrine and in a manner that avoids physical manipulation of the wound.

Abstract: The present invention relates to an efficient method for grafting a properties-imparting compound onto a polymeric substrate containing carbon-hydrogen (C—H) bonds using clip chemistry. The method of the invention includes coating the substrate with the properties-imparting compound and irradiating it with a reactive light source, and repeating this sequence at least once. The present invention further relates to surface-modified polymeric substrates grafted with a properties-imparting compound, in particular obtained with the method of the invention, medical devices comprising same, and non-medical of said surface-modified polymeric substrates.

Abstract: The present invention relates to the use of lipid/fat droplet deposits in retinas of a human subject as a biomarker for diagnosing, prognosing, and/or monitoring retinal neurodegeneration with or without an elevated intraocular pressure in glaucoma.